Literature DB >> 34133324

Identification of microenvironment related potential biomarkers of biochemical recurrence at 3 years after prostatectomy in prostate adenocarcinoma.

Xiaoru Sun1,2, Lu Wang1,2, Hongkai Li1,2, Chuandi Jin1,2, Yuanyuan Yu1,2, Lei Hou1,2, Xinhui Liu1,2, Yifan Yu1,2, Ran Yan1,2, Fuzhong Xue1,2.   

Abstract

Prostate adenocarcinoma is one of the leading adult malignancies. Identification of multiple causative biomarkers is necessary and helpful for determining the occurrence and prognosis of prostate adenocarcinoma. We aimed to identify the potential prognostic genes in the prostate adenocarcinoma microenvironment and to estimate the causal effects simultaneously. We obtained the gene expression data of prostate adenocarcinoma from TCGA project and identified the differentially expressed genes based on immune-stromal components. Among these genes, 68 were associated with biochemical recurrence at 3 years after prostatectomy in prostate adenocarcinoma. After adjusting for the minimal sets of confounding covariates, 14 genes (TNFRSF4, ZAP70, ERMN, CXCL5, SPINK6, SLC6A18, CHRM2, TG, CLLU1OS, POSTN, CTSG, NETO1, CEACAM7, and IGLV3-22) related to the microenvironment were identified as prognostic biomarkers using the targeted maximum likelihood estimation. Both the average and individual causal effects were obtained to measure the magnitude of the effect. CIBERSORT and gene set enrichment analyses showed that these prognostic genes were mainly associated with immune responses. POSTN and NETO1 were correlated with androgen receptor expression, a main driver of prostate adenocarcinoma progression. Finally, five genes were validated in another prostate adenocarcinoma cohort (GEO: GSE70770). These findings might lead to the improved prognosis of prostate adenocarcinoma.

Entities:  

Keywords:  biochemical recurrence; gene expression; prostate adenocarcinoma; targeted maximum likelihood estimation; tumor microenvironment

Year:  2021        PMID: 34133324      PMCID: PMC8266350          DOI: 10.18632/aging.203121

Source DB:  PubMed          Journal:  Aging (Albany NY)        ISSN: 1945-4589            Impact factor:   5.682


  69 in total

1.  AML1-ETO targets and suppresses cathepsin G, a serine protease, which is able to degrade AML1-ETO in t(8;21) acute myeloid leukemia.

Authors:  W Jin; K Wu; Y-Z Li; W-T Yang; B Zou; F Zhang; J Zhang; K-K Wang
Journal:  Oncogene       Date:  2012-05-28       Impact factor: 9.867

2.  Presence of the T-cell activation marker OX-40 on tumor infiltrating lymphocytes and draining lymph node cells from patients with melanoma and head and neck cancers.

Authors:  J T Vetto; S Lum; A Morris; M Sicotte; J Davis; M Lemon; A Weinberg
Journal:  Am J Surg       Date:  1997-09       Impact factor: 2.565

Review 3.  Neutrophil elastase, proteinase 3 and cathepsin G: physicochemical properties, activity and physiopathological functions.

Authors:  Brice Korkmaz; Thierry Moreau; Francis Gauthier
Journal:  Biochimie       Date:  2007-10-25       Impact factor: 4.079

4.  Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection.

Authors:  Emanuela M Ghia; Sonia Jain; George F Widhopf; Laura Z Rassenti; Michael J Keating; William G Wierda; John G Gribben; Jennifer R Brown; Kanti R Rai; John C Byrd; Neil E Kay; Andrew W Greaves; Thomas J Kipps
Journal:  Blood       Date:  2008-03-07       Impact factor: 22.113

Review 5.  Accessories to the crime: functions of cells recruited to the tumor microenvironment.

Authors:  Douglas Hanahan; Lisa M Coussens
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

Review 6.  Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience.

Authors:  M Han; A W Partin; C R Pound; J I Epstein; P C Walsh
Journal:  Urol Clin North Am       Date:  2001-08       Impact factor: 2.241

7.  Stromal protein periostin identified as a progression associated and prognostic biomarker in glioma via inducing an invasive and proliferative phenotype.

Authors:  Hongjun Wang; Yongzhi Wang; Chuanlu Jiang
Journal:  Int J Oncol       Date:  2013-03-05       Impact factor: 5.650

8.  Periostin promotes a fibroblastic lineage pathway in atrioventricular valve progenitor cells.

Authors:  Russell A Norris; Jay D Potts; Michael J Yost; Lorain Junor; Tim Brooks; Hong Tan; Stanley Hoffman; Mary M Hart; Michael J Kern; Brooke Damon; Roger R Markwald; Richard L Goodwin
Journal:  Dev Dyn       Date:  2009-05       Impact factor: 3.780

9.  CXCL5 promotes prostate cancer progression.

Authors:  Lesa A Begley; Sathish Kasina; Rohit Mehra; Shreelekha Adsule; Andrew J Admon; Robert J Lonigro; Arul M Chinnaiyan; Jill A Macoska
Journal:  Neoplasia       Date:  2008-03       Impact factor: 5.715

10.  Integrative Analysis of Periostin in Primary and Advanced Prostate Cancer.

Authors:  Carlo Cattrini; Paola Barboro; Alessandra Rubagotti; Linda Zinoli; Elisa Zanardi; Matteo Capaia; Francesco Boccardo
Journal:  Transl Oncol       Date:  2020-05-14       Impact factor: 4.243

View more
  4 in total

1.  ZAP70 Activation Compensates for Loss of Class IA PI3K Isoforms Through Activation of the JAK-STAT3 Pathway.

Authors:  Melike Demir; Onur Cizmecioglu
Journal:  Cancer Diagn Progn       Date:  2022-05-03

Review 2.  SPINKs in Tumors: Potential Therapeutic Targets.

Authors:  Chengcheng Liao; Qian Wang; Jiaxing An; Minglin Zhang; Jie Chen; Xiaolan Li; Linlin Xiao; Jiajia Wang; Qian Long; Jianguo Liu; Xiaoyan Guan
Journal:  Front Oncol       Date:  2022-02-11       Impact factor: 6.244

3.  Four specific biomarkers associated with the progression of glioblastoma multiforme in older adults identified using weighted gene co-expression network analysis.

Authors:  Yushi Yang; Liangzhao Chu; Zhirui Zeng; Shu Xu; Hua Yang; Xuelin Zhang; Jun Jia; Niya Long; Yaxin Hu; Jian Liu
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

4.  Predicting biochemical-recurrence-free survival using a three-metabolic-gene risk score model in prostate cancer patients.

Authors:  Yiqiao Zhao; Zijia Tao; Lei Li; Jianyi Zheng; Xiaonan Chen
Journal:  BMC Cancer       Date:  2022-03-04       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.